Subepithelial mucinous corneal dystrophy
A rare form of corneal dystrophy
Subepithelial mucinous corneal dystrophy (SMCD) is a rare corneal dystrophy characterized by the accumulation of mucin beneath the corneal epithelium. This condition affects the clarity of the cornea, leading to visual impairment.
Pathophysiology
Subepithelial mucinous corneal dystrophy is primarily caused by the deposition of mucin, a glycoprotein, in the subepithelial region of the cornea. This accumulation disrupts the normal architecture of the cornea, leading to opacification and visual disturbances. The exact mechanism of mucin deposition is not fully understood, but it is believed to involve genetic mutations that affect the production or clearance of mucin in the corneal tissue.
Clinical Presentation
Patients with subepithelial mucinous corneal dystrophy typically present with symptoms of blurred vision, glare, and halos around lights. These symptoms are due to the irregularities in the corneal surface caused by mucin deposits. The condition is usually bilateral, affecting both eyes, and can vary in severity.
Diagnosis
The diagnosis of subepithelial mucinous corneal dystrophy is made through a combination of clinical examination and imaging studies. Slit-lamp examination reveals characteristic subepithelial opacities. Corneal topography and optical coherence tomography (OCT) can be used to assess the extent and depth of the mucin deposits. Genetic testing may also be performed to identify any underlying mutations associated with the condition.
Management
There is currently no cure for subepithelial mucinous corneal dystrophy, and treatment is primarily aimed at managing symptoms and improving vision. Options include:
- Lubricating eye drops: To alleviate discomfort and improve vision by smoothing the corneal surface.
- Contact lenses: Specially designed lenses can help improve vision by providing a smooth refractive surface.
- Corneal transplantation: In severe cases, a corneal transplant may be necessary to restore vision.
Prognosis
The prognosis for individuals with subepithelial mucinous corneal dystrophy varies. Some patients may experience stable vision with minimal intervention, while others may require surgical treatment to maintain visual function. Regular follow-up with an ophthalmologist is essential to monitor the progression of the disease and adjust treatment as needed.
Related pages
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Get started with evidence based, physician-supervised
affordable GLP-1 weight loss injections
Now available in New York City and Philadelphia:
- Semaglutide starting from $59.99/week and up
- Tirzepatide starting from $69.99/week and up (dose dependent)
✔ Evidence-based medical weight loss ✔ Insurance-friendly visits available ✔ Same-week appointments, evenings & weekends
Learn more:
Start your transformation today with W8MD weight loss centers.
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian